Publications by the researcher in collaboration with Nieves Purificacion Martinez Lago (11)

2024

  1. Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON–SEOM registry

    Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1674-1686

2023

  1. Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry

    Journal of Cancer Research and Clinical Oncology, Vol. 149, Núm. 7, pp. 4077-4089

  2. The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy

    Therapeutic Advances in Medical Oncology, Vol. 15

2022

  1. Efficacy and safety of FOLFIRI/aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin-based regimen

    PLoS ONE, Vol. 17, Núm. 6 June

  2. Sex and gender disparities in patients with advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry

    ESMO Open, Vol. 7, Núm. 3

2021

  1. Dynamic perspective of the neutrophil-to-lymphocyte ratio in metastatic gastric cancer

    Journal of B.U.ON., Vol. 26, Núm. 5, pp. 2131-2140

  2. Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain

    BMC Cancer, Vol. 21, Núm. 1

  3. Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data

    Scientific Reports, Vol. 11, Núm. 1

  4. Real-life use of ramucirumab in gastric cancer in Spain: The RAMIS study

    Future Oncology, Vol. 17, Núm. 14, pp. 1777-1791

2020

  1. Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram

    Clinical and Translational Oncology, Vol. 22, Núm. 3, pp. 351-359

2019

  1. Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers

    Cancer Medicine, Vol. 8, Núm. 3, pp. 882-889